| Date | Title | Description | Source |
| 12.05.2023 | Carisma Therapeutics Reports First Quarter 2023 Financial Re... | Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients w... | healthcap.... |
| 05.05.2023 | Carisma Therapeutics to Present at Upcoming Healthcare Indus... | PHILADELPHIA, May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. CARM ("Carisma"), a cl... | einpresswi... |
| 05.04.2023 | Carisma Therapeutics Reports Fiscal 2022 Financial Results a... | Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol “CARM”
Cash positi... | healthcap.... |
| 08.03.2023 | Carisma Therapeutics Closes Merger with Sesen Bio | Shares of Carisma to commence trading on Nasdaq under new ticker symbol “CARM” on March 8, 2023
Res... | healthcap.... |
| 03.03.2023 | Sesen Bio Stockholders Approve Merger with Carisma Therapeut... | Declares Special Dividend in the Aggregate of $75 Million
Approximately 88% Voted in Favor of the M... | healthcap.... |
| 16.02.2023 | Sesen Bio and Carisma Therapeutics Announce Increased Specia... | Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Continge... | healthcap.... |
| 09.02.2023 | Carisma Therapeutics Appoints Moderna CSO of External Resear... | PHILADELPHIA, Feb. 7, 2023 /PRNewswire/ — Carisma Therapeutics Inc., a clinical stage biopharmaceuti... | healthcap.... |
| 02.02.2023 | Carisma Therapeutics Appoints Leading Solid Tumor Immunother... | Expansion of Scientific Advisory Board provides additional expertise in development capabilities
PH... | healthcap.... |
| 03.01.2023 | Sesen Bio and Carisma Therapeutics Announce Substantial Incr... | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend i... | healthcap.... |
| 22.09.2022 | Sesen Bio and Carisma Therapeutics Announce Merger Agreement | Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macro... | healthcap.... |
| 11.01.2022 | Moderna and Carisma establish collaboration to develop in vi... | Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and... | wellington... |
| 09.04.2021 | CARISMA Therapeutics to Present Data at The American Associa... |
PHILADELPHIA, April 9, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmac... | prnewswire... |
| 18.03.2021 | CARISMA Therapeutics Announces First Patient Dosed in Landma... |
PHILADELPHIA, March 18, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharma... | prnewswire... |
| 02.03.2021 | CARISMA Therapeutics Inks $59M Series B |
PHILADELPHIA, PA, CARISMA Therapeutics added $12M to its Series B.
>> Click here for more f... | vcnewsdail... |
| 01.03.2021 | 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutic... | Press Release
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 ... | globenewsw... |
| 01.03.2021 | IP : CARISMA Therapeutics Inc. - CARISMA Therapeutics Comple... | Funds to Support Advancement of Pipeline and Discovery Programs, Including Recently Initiated Phase ... | marketscre... |
| 01.03.2021 | Daily funding roundup - March 1st, 2021 | Skydio raised $170M; Artiva landed $120M; FogPharma secured $107M; Axonius picks up $100M
Skydio: S... | vator.tv/n... |
| 01.03.2021 | 4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Secon... | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm fo... | 4biocapita... |
| 01.03.2021 | IP GROUP PLC
IP : CARISMA Therapeutics Inc. - CARISMA Thera... | Funds to Support Advancement of Pipeline and Discovery Programs, Including Recently Initiated Phase ... | marketscre... |
| 01.03.2021 | CARISMA Therapeutics Completes Series B Financing Totaling $... |
PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company... | prnewswire... |
| 08.01.2021 | CARISMA Therapeutics Completes Series B Funding for $47 Mill... | CARISMA Therapeutics announced today that it has completed its Series B equity financing providing f... | wellington... |
| 07.01.2021 | CARISMA Therapeutics Completes $47 Million Series B Funding | CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovat... | citybizlis... |
| 07.01.2021 | CARISMA THERAPEUTICS COMPLETES SERIES B FUNDING FOR $47 MILL... | - | solasta-ve... |
| 07.01.2021 | CARISMA Therapeutics Completes Series B Funding for $47 Mill... |
PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company ... | prnewswire... |
| 07.01.2021 | CARISMA Therapeutics Lands $47M Series B |
PHILADELPHIA, PA, CARISMA Therapeutics has completed its Series B equity financing providing for g... | vcnewsdail... |
| 23.03.2020 | Startup Spotlight: Carisma Therapeutics wants to make a cell... | When Michael Klichinsky was rotating through University of Pennsylvania hospitals as a pharmacy stud... | statnews.c... |
| 14.02.2020 | Carl June on CRISPR, CAR–T and how the Vietnam War dropped ... | In August of 2011, Carl June and his team published a landmark paper showing their CAR–T treat... | endpts.com... |
| 08.08.2019 | Carisma Therapeutics Raised Nearly $60M in Series A Funding.... | Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for ... | citybizlis... |
| 08.08.2019 | Carisma Therapeutics raised nearly $60M in Series A funding.... | Carisma Therapeutics, working on a cellular therapy aimed at fighting solid tumors, is planning for ... | technical.... |
| 28.06.2018 | Term Sheet — Thursday, June 28 | LYFTED
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From Ext... | fortune.co... |
| 27.06.2018 | Carisma Therapeutics announces $53 million Series A financin... | Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately-held biotechnology company focus... | wellington... |
| 27.06.2018 | Carisma Therapeutics Inks $53M Series A |
PHILADELPHIA, PA, Carisma Therapeutics announced the close of a $53 million Series A financing.
&... | vcnewsdail... |
| 27.06.2018 | Carisma Therapeutics Raises $53M in Series A Financing | Carisma Therapeutics Inc., formerly known as Carma Therapeutics, a Philadelphia, PA-based biotechnol... | finsmes.co... |
| 27.06.2018 | Carisma Therapeutics Inc - Announces a $53m Series A Financi... |
Carisma Therapeutics Inc
., formerly CARMA Therapeutics, a privately-held biotechnology company f... | ipgroupplc... |
| - | CARISMA Therapeutics Completes Series B Financing Totaling $... | PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company f... | oaoa.com/n... |
| - | CEVEC and CARISMA Therapeutics sign license agreement for th... | Cologne, Germany and Philadelphia, PA, USA February 2, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) and... | creathor.c... |
| - | First-of-its-kind Engineered Macrophage Cell Therapy Platfor... | Study highlights previously untapped potential of genetically engineered macrophages in immunotherap... | healthcap.... |
| - | CARISMA Therapeutics Completes Series B Funding for $47 Mill... | PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company foc... | healthcap.... |
| - | CARISMA Therapeutics Appoints Richard Morris as Chief Financ... | PHILADELPHIA, June 8, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceuti... | healthcap.... |
| - | CARISMA Therapeutics Completes Series B Financing Totaling $... | PHILADELPHIA, March 1, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company fo... | healthcap.... |
| - | Carisma Therapeutics to Present and Meet with Potential Inve... | PHILADELPHIA, May 21, 2020 /PRNewswire/ — Carisma Therapeutics Inc., a biopharmaceutical company foc... | healthcap.... |
| - | Carisma Therapeutics Announces Collaboration with Merck to E... | PHILADELPHIA, December 2, 2021 — Carisma Therapeutics Inc., a clinical stage biopharmaceutical compa... | healthcap.... |
| - | CARISMA Therapeutics Announces First Patient Dosed in Landma... | Clinical trial to study CT-0508 in patients with metastatic HER2 overexpressing solid tumors
PHILAD... | healthcap.... |
| - | Carisma Therapeutics Announces Appointment Of Michael Klichi... | – Klichinsky, co-founder of Carisma Therapeutics, co-invented the company’s proprietary and first-of... | healthcap.... |
| - | CARISMA Therapeutics Announces U.S. Food and Drug Administra... | PHILADELPHIA, Sept. 22, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceu... | healthcap.... |
| - | Carisma Therapeutics to Present Latest Data from Phase 1 Cli... | PHILADELPHIA, PA – May 26, 2022 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical comp... | healthcap.... |
| - | CARISMA Therapeutics to Present Data at The American Associa... | – First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows sig... | healthcap.... |
| - | CARISMA Therapeutics Establishes Collaboration with Leading ... | PHILADELPHIA, April 26, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceu... | healthcap.... |
| - | Carisma Therapeutics Appoints Sanford Zweifach as Chairman t... | PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company f... | healthcap.... |
| - | Moderna and Carisma Establish Collaboration to Develop in vi... | Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP te... | healthcap.... |
| - | Carisma Therapeutics Names Dr. Robert Petit as Chief Scienti... | PHILADELPHIA, June 3, 2019 /PRNewswire/ — Carisma Therapeutics Inc., a preclinical-stage biopharmace... | healthcap.... |
| - | Carisma Therapeutics to Host Webcast on Phase 1 Clinical Tri... | PHILADELPHIA, June 17, 2022 /PRNewswire/ — Carisma Therapeutics, a clinical stage biopharmaceutical ... | healthcap.... |
| - | CARISMA Therapeutics Announces FDA Clearance of IND Applicat... | PHILADELPHIA, July 27, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company fo... | healthcap.... |
| - | Moderna and Carisma Establish Collaboration to Develop in vi... | Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP te... | healthcap.... |
| - | Carisma Therapeutics | “Carisma Therapeutics is pioneering the development of CAR-Macrophages, a disruptive approach to sol... | fastfounde... |
| - | Carisma Therapeutics to Present Engineered Cell Therapy Data... | Findings further indicate the potential of engineered macrophages as a new treatment pathway for har... | healthcap.... |
| - | Carisma Therapeutics Presents Data from Phase I Clinical Tri... | PHILADELPHIA, November 12, 2021, 12:10 PM ET— Carisma Therapeutics Inc., a clinical stage biopharmac... | healthcap.... |
